All In Biotech

Drug Trial Radar · NCT04423211

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 804 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

804

Planned (sponsor's estimate)

Start

Oct 8, 2020

Primary completion

Dec 31, 2032

Study completion Dec 31, 2032

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

Conditions

  • Biochemically Recurrent Prostate Carcinoma
  • Metastatic Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • 3-Dimensional Conformal Radiation TherapyRadiation

    Undergo 3D CRT

  • ApalutamideDrug

    Given PO

  • Computed TomographyProcedure

    Undergo PET/CT

  • DegarelixDrug

    Given SC

  • External Beam Radiation TherapyRadiation

    Undergo EBRT

  • Fluciclovine F18Other

    Given IV

  • Goserelin AcetateDrug

    Given SC

  • Intensity-Modulated Proton TherapyProcedure

    Undergo IMPT

  • Intensity-Modulated Radiation TherapyRadiation

    Undergo IMRT

  • Leuprolide AcetateDrug

    Given IM

  • Magnetic Resonance ImagingProcedure

    Undergo PET/MR

  • Positron Emission TomographyProcedure

    Undergo PET/CT or PET/MR

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • RelugolixDrug

    Given PO

  • Stereotactic Body Radiation TherapyRadiation

    Undergo SBRT

  • TriptorelinDrug

    Given IM

  • Volume Modulated Arc TherapyRadiation

    Undergo VMAT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From randomization to radiographic progression by conventional imaging or positron emission tomography (PET), symptomatic disease or death, whichever occurs first, assessed up to 10 years
  2. PFS prolongation in patients without PET-evidence of extrapelvic metastasesTime frame: Up to 10 years
  3. PFS prolongation in patients with PET-evidence of extrapelvic metastasesTime frame: Up to 10 years
  4. Quality of life (QOL)Time frame: Up to 24 months

Locations

341 sites in 1 country. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Recruiting

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Recruiting

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Recruiting

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Recruiting

  • Anchorage Oncology Centre

    Anchorage, Alaska · Suspended

  • Katmai Oncology Group

    Anchorage, Alaska · Recruiting

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska · Recruiting

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Recruiting

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Recruiting

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Recruiting

  • Mercy Cancer Center - Carmichael

    Carmichael, California · Recruiting

  • Mercy San Juan Medical Center

    Carmichael, California · Recruiting

  • City of Hope Corona

    Corona, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California · Recruiting

  • UC San Diego Health System - Encinitas

    Encinitas, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Active not recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Active not recruiting

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Mercy Cancer Center

    Merced, California · Suspended

  • VA Palo Alto Health Care System

    Palo Alto, California · Active not recruiting

  • Mercy Cancer Center - Rocklin

    Rocklin, California · Recruiting

  • Mercy Cancer Center - Sacramento

    Sacramento, California · Recruiting

  • UC San Diego Medical Center - Hillcrest

    San Diego, California · Recruiting

  • Pacific Central Coast Health Center-San Luis Obispo

    San Luis Obispo, California · Recruiting

  • Mission Hope Medical Oncology - Santa Maria

    Santa Maria, California · Recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Recruiting

  • Saint Joseph's Medical Center

    Stockton, California · Recruiting

  • City of Hope Upland

    Upland, California · Recruiting

  • BASS Medical Group - Lennon

    Walnut Creek, California · Active not recruiting

  • Woodland Memorial Hospital

    Woodland, California · Recruiting

  • Rocky Mountain Cancer Centers-Aurora

    Aurora, Colorado · Active not recruiting

  • Rocky Mountain Cancer Centers-Boulder

    Boulder, Colorado · Active not recruiting

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado · Recruiting

  • Rocky Mountain Cancer Centers-Penrose

    Colorado Springs, Colorado · Recruiting

  • Saint Francis Cancer Center

    Colorado Springs, Colorado · Recruiting

Showing 40 of 341 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.